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Abstract The evaluation and management of patients
with residual Cushing’s disease is one of the more complex
issues facing neurosurgeons and neuroendocrinologists in
clinical practice. There is considerable controversy over
several relevant issues such as the timing of the assessment
of whether a patient is in remission, what biochemical
parameters deﬁne remission, the most appropriate course of
action to take after residual disease has been deﬁned, etc. As
a consequence of the controversies, treating physicians
develop notions and fall into certain practice patterns based
on evidence of varying levels, their anecdotal experiences,
and information gleaned from scientiﬁc meetings. This
practice pattern, we believe, constitutes the ‘‘art of medi-
cine.’’ We conducted a PubMed literature search to identify
manuscripts containing data relevant to Cushing’s disease,
outcomes of various therapeutic modalities, and recur-
rences. Reference lists were used to identify additional rel-
evant manuscripts. We focused our review on manuscripts
that included reasonably large series of patients, those
reﬂecting the experience of pituitary centers and physicians
recognized as experts in the ﬁeld, and those papers felt to
represent seminal contributions to the literature. Further-
more, trends in the evaluation and management of relevant
patients have been incorporated by the senior author who
has seen and evaluated over 750 patients with documented
Cushing’s syndrome over the past 18 years in clinical
practice. An analysis of current evidence indicated that,
despite advances in neurosurgical techniques and recent
developments in adjuvant therapies, patients with residual
Cushing’s disease present signiﬁcant management chal-
lenges to treating physicians. In this era, however, it is
indeed possible to gain control of the hypercortisolism in
most patients. Despite the wide variability in research
methodology designed to collect relevant data, a step-wise
approach to the management of these patients can be
achieved. A logical step-wise approach to the evaluation of
postoperative patients with Cushing’s disease is essential.
Patients with residual disease require the development of an
individualized plan of management that takes into account
numerous factors pertaining to status of disease, the expe-
rience of treating physicians, and available therapeutic
modalities.
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Introduction
Patients with residual Cushing’s disease after initial sur-
gery present a wide variety of challenges to their healthcare
team. After having gained experience with these fascinat-
ing patients, we have concluded that treating physicians
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DOI 10.1007/s11060-009-9888-2must evaluate and manage patients with residual or recur-
rent Cushing’s disease in a logical step-wise fashion. One
must ﬁrst verify the original diagnosis and then re-evaluate
the status of the underlying disease. Thereafter, it is pos-
sible to outline an approach to subsequent management,
including treatment of associated morbidities. Patients and
their families require a great deal of support, education, and
guidance in the decision-making processes regarding fol-
low-up and treatment. This review is intended to provide
an overview of our biased approach to these patients based
on our experiences, some of the data gleaned from a review
of the literature, and information derived from discussions
with leaders in the ﬁeld.
The efﬁcacy of transsphenoidal pituitary surgery
in patients with Cushing’s disease
Transsphenoidal surgery is the initial treatment of choice
for most patients with Cushing’s disease. The principal
goals of surgery include complete resection of the ACTH-
secreting pituitary tumor, resolution of the hypercortiso-
lemic state and its associated morbidities, and restoration
of the normal dynamic function of the hypothalamic-
pituitary-adrenal axis. When possible, the pituitary gland
should be spared so that patients do not require hormone
replacement therapy.
Most of the published data regarding the outcomes of
initial surgery are derived from retrospective case series
[1–3, 6, 10, 13, 14, 22, 27, 31, 36, 37]. These observations,
while forming the basis of the knowledge we share with
our patients, must be reviewed with the understanding that
uniform criteria regarding the deﬁnitions of cure and
recurrence have not been applied across published reports.
This is in part due to the fact that, even amongst experts in
the ﬁeld, there is still disagreement as how to best distin-
guish between patients in remission and those with residual
disease [8, 38–40]. Further, many of the available studies
are not of sufﬁcient duration to allow for recurrence in
some patients with Cushing’s disease.
Published series from experienced centers demonstrate
that remission following initial surgery can be expected in
70–90% of patients with Cushing’s disease caused by mic-
roadenomas. Remission is seen in 50–65% of patients with
macroadenomas (Tables 1, 2). Recurrent hypercortisolism
affects approximately 10% of patients with microadenomas
andasmanyas30%ofpatients withmacroadenomas.While
most recurrences occur within 5 years of surgery, some are
not evident until a decade or more after an initially suc-
cessful surgery. Thus, life-long follow-up with periodic
reassessments is required even when patients are thought to
have been cured.
Initial postoperative assessment of patients
with Cushing’s disease
Several algorithms or approaches have been proposed to
assess cortisol secretion in the immediate postoperative
period in order to identify patients with persistent disease
and to plan for immediate additional treatment [6, 8, 13,
31, 39]. Once again, there is no consensus regarding
the deﬁnition and best means of identifying patients
with residual Cushing’s disease. It is clear, however, that
patients with elevated postoperative serum cortisol
concentrations and elevated urine cortisol excretion rates
have had unsuccessful surgeries and require additional
treatment.
We expect a period of transient adrenal insufﬁciency,
lasting an average of 12 months, in patients who have had
successful surgery. The adrenal insufﬁciency, also referred
to as central adrenocortical insufﬁciency, is due to pro-
found suppression of the hypothalamus and residual normal
anterior pituitary corticotrophs by the pre-existing hyper-
cortisolism. Patients who have normal cortisol levels and
fail to develop adrenal insufﬁciency are presumed to have
residual tumoral corticotrophs that are secreting sufﬁcient
amounts of ACTH to maintain adrenal function. However,
Table 1 Published data regarding the outcomes of surgical therapy
of all patients with Cushing’s disease
First author Total #
patients
Remission
(%)
Recurrence
(%)
Mean
follow-up
(months)
Invitti [14] 288 69 17
Bochicchio [2] 668 76 13 46
Blevins [1]9 6 8 5 1 6 4 9
Sonino [36] 103 77 26 72
Mampalam [22] 216 79 5 46
Swearingen [37] 161 85 7 24
Nakane [27] 100 92 9 39
Esposito [6]4 0 8 0 3 4 3 3
Imaki [13]4 9 8 0 1 0 8 8
Pereira [31]7 8 7 2 1 2 8 4
Hammer [10] 289 82 9 131
Table 2 Published data regarding outcomes of surgical treatment of
patients with Cushing’s disease due to pituitary macroadenomas
First author Total #
patients
Remission
(%)
Recurrence
(%)
Mean
follow-up
(months)
Blevins [1]2 16 7 3 6 6 2
Swearingen [37] 17 65 18 104
De Tommasi [3]3 7 6 8 1 2 4 2
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123recurrent hypercortisolism is seen in only one-quarter of
patients with normal postoperative serum cortisol levels
[2]. In fact, recurrence is also seen in 4–11% of patients
who develop central adrenocortical insufﬁciency after
surgery [2, 13, 40]. Thus, a simple measurement of the
serum cortisol level after surgery does not always indicate
the presence or absence of disease.
Estrada et al. showed that patients in whom the diurnal
variation in cortisol secretion has been restored to normal
are far less likely to develop recurrent hypercortisolism
(3%) than those who have persistent abnormalities in the
diurnal variation of cortisol secretion (50%) [8]. We ﬁnd
this observation to be true in our practice and believe loss
of diurnal variation to be the sine qua non of pathologic
hypercortisolism. When it is unclear to us as whether or not
a patient has residual or recurrent Cushing’s disease we
employ tests of salivary cortisol levels at 9 time points
throughout the day to assess diurnal variation in our
patients (Fig. 1). Others have suggested that suppression of
cortisol secretion by dexamethasone is a reliable indicator
of remission [23]. We have, however, managed several
patients with suspected persistent or recurrent disease
whose serum cortisol levels were suppressed to\2 mcg/dl
after administration of 1 mg dexamethasone who went on
to have overt evidence for recurrent disease. In several
cases these patients had demonstrated abnormal diurnal
variations in their salivary cortisol levels when their cor-
tisol levels were ‘‘normal’’ and suppressible. Thus, we do
not consider the suppression of cortisol levels following the
administration of dexamethasone in postoperative patients
to be evidence always in support of remission.
We ﬁnd an immediate postoperative cortisol level to be
useful only in identifying those patients with ongoing,
ﬂagrant hypercortisolism. These patients are usually obvi-
ous to treating physicians as they demonstrate continued
impaired glycemic control, hypertension, and persistent
plethora throughout the postoperative period. Caution is
advised when considering additional treatment for those
patients who have normal immediate postoperative cortisol
levels, as only a proportion will indeed have residual dis-
ease in need of additional treatment [2]. We prefer to delay
our formal comprehensive assessment of cortisol secretion
until the ﬁrst postoperative visit, scheduled for 6 weeks
after initial surgery. We have found that this approach
minimizes physician and patient frustration as well as the
prescription of potentially unnecessary adjuvant therapy.
We assert that cortisol levels obtained 6–12 weeks after
surgery in patients with Cushing’s disease are more useful
for predicting the likelihood of long-term remission than
serum cortisol levels obtained within 2 weeks of surgery.
This approach is further supported by a review of the data
of Toms et al. [38] illustrating cortisol levels reach their
nadir several weeks after surgery.
Evaluation of the reasons for surgical failure
It is essential to consider several possible scenarios
when faced with patients who have sufﬁcient clinical and
biochemical evidence of residual Cushing’s disease
(Tables 3, 4). Was the diagnosis of Cushing’s disease,
implicating the presence of an ACTH-secreting pituitary
Fig. 1 Salivary cortisol proﬁles
in a patient with (a) Cushing’s
disease and (b) normal function
of the hypothalamic-pituitary-
adrenal unit
Table 3 A logical approach to the postoperative evaluation of
patients with suspected residual or recurrent Cushing’s disease
Step 1 Conﬁrm presence pathologic ACTH hypersecretion exists
after surgery
Elevated Urine Free Cortisol on 2–3 occasions
Abnormal diurnal variation in serum or salivary cortisol
levels
Abnormal Dex-CRH stimulation test
Substantiating clinical evidence
Step 2 Conﬁrm preoperative diagnosis of ACTH-dependent
hypercortisolism
Review data to determine if pathologic hypercortisolism
was indeed present prior to surgery
Review preoperative MRI studies to determine if
pituitary tumor was present
Step 3 Review histopathology for evidence of ACTH-producing
pituitary tumor
ACTH-immunopositive lesion?
Crooke’s Hyaline change present?
Step 4 Consider differential diagnosis
MRI to evaluate for pituitary tumor
Inferior petrosal sinus sampling if surgical pathology
was negative
Overnight 8 mg Dexamethasone suppression test to
evaluate pathophysiology of ACTH excess
Octreoscan if ectopic ACTH secretion suspected
J Neurooncol (2009) 94:313–319 315
123tumor, correct? Patients with the occult syndrome of ectopic
ACTH hypersecretion, and especially those with bronchial
carcinoid tumors, often mimic, both clinically and bio-
chemically, patients with ACTH-secreting pituitary tumors.
In our experience, however, a signiﬁcant portion of the
patients whounderwentexplorationforapituitarytumoryet
were ultimately found to have the syndrome of ectopic
ACTH hypersecretion had biochemistry suggestive of the
correct diagnosis. Thus, a careful review of available test
results is an essential step in the evaluation of patients who
have failed surgery. In many cases, it is useful to repeat
dynamic tests of the hypothalamic-pituitary-adrenal axis
in order to better understand the pathophysiology of the
hypercortisolism.
Review of the histopathology report is critical when
evaluating patients in the postoperative period. Demon-
stration of an ACTH-secreting pituitary tumor in a patient
who has persistent hypercortisolism can conﬁrm that the
preoperative diagnosis was correct and might suggest that
removal of the tumor was incomplete. Microscopic evi-
dence of invasion into surrounding structures has been
demonstrated in 8% of patients with ACTH-secreting
microadenomas and 62% of patients with ACTH-secreting
macroadenomas [34]. Thus, it is not surprising that some
patients will have residual disease or experience disease
recurrence despite gross total resection of their pituitary
tumors. In one series, the surgical failure rate was 26% in
patients who did not have visible tumors on preoperative
MRI scans of the sella [2]. By comparison, the failure rate
was only 13% in patients who had a demonstrable tumor.
The absence of conﬁrmatory histopathology is associated
with a higher rate of surgical failure (47%) than when an
ACTH-producing pituitary tumor is conﬁrmed (17%) [2].
The absence of Crooke’s hyaline change within the
resected pituitary tissue suggests that a preoperative diag-
nosis of hypercortisolism was perhaps incorrect [33].
Inferior petrosal sinus sampling with corticotropin-
releasing-hormone stimulation, if not previously per-
formed, may be indicated for those patients in whom an
ACTH-secreting pituitary tumor was not identiﬁed at the
time of surgery. We strongly advise the procedure when a
review of the available endocrine data is not speciﬁc for the
diagnosis of an ACTH-secreting pituitary tumor and
especially when the data are thought to be consistent with
the syndrome of ectopic ACTH hypersecretion.
Unfortunately, a signiﬁcant proportion of transsphenoi-
dal surgical procedures are still being performed by inex-
perienced neurosurgeons. Practice surveys have clearly
illustrated that complication rates are higher following
attempts at transsphenoidal surgery by relatively inexperi-
enced surgeons compared with more experienced pituitary
surgeons [32]. It is generally accepted that cure rates are
higher in the hands of experienced surgeons. Thus, the skill
of the operating neurosurgeon must be taken into account
when evaluating and planning therapy for patients who
have failed surgery.
General approach to the management of patients
with residual Cushing’s disease
Once a diagnosis of persistent Cushing’s disease has been
conﬁrmed, one must consider treatment options in the
context of the affected patient. Patients should be advised of
the available treatments, the expected outcomes, risks,
inconveniences, and costs so they can make informed
decisions on how best to proceed. Ideal therapeutic strate-
giesaredirectedatresolutionofthehypercortisolismaswell
as control of the offending tumor. In many cases, however,
these objectives must be dealt with independently. Despite
the fact that there are numerous therapies for patients with
residual or recurrent hypercortisolism, many will unfortu-
nately never achieve complete remission of their disease.
Additional goals of therapy include management of adverse
consequences of therapy, such as hypopituitarism, and
correction or control of the manifestations of hypercorti-
solism including hyperglycemia, hypertension, osteopenia,
management of infections, etc.
The efﬁcacy of repeat pituitary surgery
Repeat transsphenoidal surgery should be considered for all
patients with residual Cushing’s disease. Those with mac-
roadenomas and an accessible tumor that is visible on MRI
may beneﬁt from additional decompression and the sub-
sequent fall in ACTH and cortisol levels even though
complete remission in these patients is uncommon fol-
lowing a second procedure [1, 3, 20, 32, 37]. We do not
Table 4 Potential causes of failed surgery in patients with Cushing’s
disease
Incorrect preoperative diagnosis
Syndrome of ectopic ACTH hypersecretion
Ectopic pituitary adenoma (cavernous sinus, suprasellar, stalk)
Corticotroph hyperplasia
Pseudo-Cushing’s syndrome
Factitious Cushing’s syndrome
Incomplete or failed tumor resection
Inexperienced neurosurgeon
Invasive disease
Negative MRI
Negative histopathology
316 J Neurooncol (2009) 94:313–319
123favor repeat surgery for patients who have a majority of
their tumor located within the cavernous sinuses or in other
surgically inaccessible regions. Patients with microadeno-
mas that are either visualized on MRI or else suspected to
be present based on the results of inferior petrosal sinus
sampling are considered for repeat surgery, especially
when an inexperienced neurosurgeon performed the initial
procedure. Approximately one-half to three-quarters of
patients with microadenomas can be expected to enter
remission following repeat surgery when performed by an
experienced neurosurgeon (Table 5).
The efﬁcacy of radiotherapy
Radiotherapy has long been used in the management of
patients with Cushing’s disease who were failed by pitui-
tary surgery [29].
Fractionated conventional external beam radiotherapy
has been utilized extensively and is generally well toler-
ated. Remission can be expected in about 50% of adults
and 80% of children [29, 30]. Unfortunately, the response
to treatment is delayed; only 50% of patients enter remis-
sion 18 months after treatment. Normalization of cortisol
secretion may occur between 6 and 60 months [7, 21, 41].
Stereotactic radiosurgery, most commonly in the form of
Gamma Knife
 radiosurgery, has been increasingly
employed in the management of patients with pituitary
tumors in attempt to minimize unintentional irradiation to
local neural and vascular structures while delivering a high
dose of radiation precisely focused on the target tumor vol-
ume. The successful normalization of cortisol levels in 27–
66% of adult patients is comparable to that observed when
conventional external radiotherapy is employed [4, 11, 16,
17, 19, 21, 24, 26, 29, 35, 41]. The mean time to normali-
zation of cortisol levels however is much shorter, occurring
on average in 6–8 months, with a reported range of 6–
36 months [4, 5, 16, 24–26, 35]. This observation suggests
that while stereotactic radiosurgery is not necessarily more
efﬁcacious than conventional external radiotherapy, it does
normalize cortisol levels more quickly and therefore limits
the exposure to hypercortisolemia and its consequences.
Stereotactic radiosurgery appears to provide control of
tumor burden in 66–98% of patients. Data on recurrence
rates are rare in the literature, though rates reported are less
than 10% [12, 21, 35]. In contrast, recurrence rates fol-
lowing conventional external radiotherapy are reported to
be as high as 45% with relapses occurring as late as
84 months following therapy [12, 19].
Potential late sequelae of either type of radiation therapy
include hypopituitarism, radiation-induced optic neuropa-
thy, temporal lobe necrosis, and secondary carcinogenesis.
The reported incidence of optic neuropathy and temporal
lobe necrosis with stereotactic neurosurgery is less than 2%
and between 1% and 5%, respectively; only isolated cases
of secondary neoplasms have been reported in the literature
[29]. In contrast, there is an estimated two-fold increased
risk of developing a second neoplasm following conven-
tional external radiotherapy. Pituitary hormone deﬁciencies
are reported with both modalities in one- to two-thirds of
patients as late as 10 years post-treatment [4, 12, 18, 35].
We only employ radiotherapy in the management of
patients with persistent Cushing’s disease when we have
conﬁrmed the pituitary as the site of ACTH hypersecretion.
We employ stereotactic radiosurgery whenever possible
and especially in younger patients. Suitable patients for
stereotactic radiosurgery include those with a demonstrable
lesion on MRI, those with intrasellar microadenomas
identiﬁed on MRI preoperatively and histologic evidence
of tumors at the time of surgery regardless of whether
tumors are seen on postoperative imaging studies, and
those who have cavernous sinus or bony invasion in pat-
terns that permit treatment planning such that the optic
pathways and other neural and vascular structures will not
receive an inappropriate amount of radiation. Patients with
suprasellar lesions in close proximity to the optic pathways
are generally referred for conventional radiotherapy.
Patients with invasive macroadenomas are probably best
treated with conventional radiotherapy unless a region of
interest for treatment can be developed to encompass the
entire original tumor bed in order to permit irradiation of
residual microscopic invasive tumor.
Medical therapy to lower cortisol levels
A number of steroid biosynthesis inhibitors can be
employed in order to gain control of hypercortisolism.
Table 5 Published data
regarding outcomes of repeat
surgery in patients with
Cushing’s disease
First author Total #
patients
Cure (%) Recurrence (%)
Blevins [1] 9 44 (microadenomas)
4 0 (macroadenomas)
Ram [32]1 7 7 1 2 5
Swearingen [37]2 8 4 6
Locatelli [20]1 2 6 7
J Neurooncol (2009) 94:313–319 317
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health status of patients in the event that repeat surgery will
be delayed by more than 4–8 weeks and while awaiting the
beneﬁcial effects of radiotherapy.
We prefer to employ ketoconazole as ﬁrst-line therapy.
We initiate therapy with a dose of 200 mg twice daily. The
dose is escalated as needed at 2–4 week intervals to a
maximum dose of 400 mg four times daily to achieve
normal urinary cortisol excretion rates. Aminoglutethimide
and metyrapone are useful, either alone or in combination
with ketoconazole, when cortisol levels are refractory to
treatment or the side effects of ketoconazole are intolera-
ble. These medications are becoming increasingly difﬁcult
to obtain by prescription. We prescribe mitotane as a drug
of last resort in patients with Cushing’s disease. We have
found that most patients will not tolerate the side effects of
the drug even when the medication is scheduled in a
fashion to limit toxicity. Regardless of the drug employed,
surveillance of urinary cortisol excretion rates at regular
intervals is necessary in order to identify those refractory to
treatment, those who suffer from breakthrough hypercor-
tisolism, and also to detect hypocortisolism in those who
may have responded to radiotherapy. In general, we dis-
continue medical therapy for 6 weeks to permit reassess-
ment of cortisol excretion rates in patients who have been
treated with radiotherapy when their 24-h urinary cortisol
levels are in or even below the lower quartile of the normal
range in the assay employed.
Bilateral adrenalectomy in the management
of refractory patients
Bilateral adrenalectomy should deﬁnitely be employed
when all else has failed and the patient is in grave danger
due to the consequences of hypercortisolism [9, 28]. The
relative success and lower risk of complications from
laparoscopic bilateral adrenalectomy indicates that this
therapeutic modality might be employed earlier in the
course of treatment for some patients with Cushing’s dis-
ease. Still, a decision to recommend adrenalectomy is not
to be taken lightly as the operative mortality approaches
5% and as many as 20% of patients suffer from perioper-
ative complications including deep vein thrombosis,
delayed wound healing, bleeding disorders, and perioper-
ative infections [15]. Nelson’s syndrome develops after
bilateral adrenalectomy in approximately one-ﬁfth of
patients and may require additional therapeutic interven-
tion directed at the enlarging pituitary tumor. It is generally
accepted that the risk of developing Nelson’s syndrome
following adrenalectomy can be reduced by one-half by
delivery of conventional or stereotactic radiotherapy to the
pituitary tumor prior to adrenalectomy.
Conclusions
In conclusion, we recommend an individualized approach
to the evaluation and management of the patient with
residual Cushing’s disease following initial pituitary sur-
gery. Decisions regarding the need for additional treatment
are based on the status of the disease activity and conﬁr-
mation of the original diagnosis based upon a review of the
results of endocrine tests and histopathology as well as
postoperative radiological studies. The expertise and
capabilities of treating physicians as well as the availability
of modalities that can be employed to deliver alternative
therapies should be considered. Complex patients should
be referred to a tertiary medical center for management by
an experienced multi-disciplinary team in patients who
have persistent or recurrent hypercortisolism.
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